

Anti-B7-H3/CD276 Antibody (MirzotamAb)

Introduction

Mirzotamab is an IgG1k monoclonal antibody targeting CD276/B7-H3 with anti-tumor activity. Mirzotamab can be combined with the BCL inhibitor Clezutoclax to form Mirzotamab clezutoclax, which can participate in taxane research on relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody-drug conjugate (ADC).

Product parameters

Alternative Names	Mirzotamab
Target Accession	Q5ZPR3
Target	B7-H3 / CD276
CAS number	2229859-11-2
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

